Puma Biotechnology(PBYI)

• Established commercial infrastructure with $236M FY2025 revenue from FDA-approved oncology drug with expanding indications across breast cancer, lung cancer, and solid tumors
• Profitable operations ($22M net income FY2025) with strong cash position ($69M) enabling R&D investment in 50 active clinical trials
• Focused oncology pipeline with 2 Phase 3 programs (neratinib in breast cancer) and multiple Phase 2 programs (Alisertib in lung cancer, combinations with standard therapies)

Generated by Claude from Puma Biotechnology's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pan-HER inhibitor approved across three oncology indications with continued label expansion; sole revenue driver supporting company operations and R&D investment.